You are here » Home » Companies » Company Overview » BDH Industries Ltd

BDH Industries Ltd.

BSE: 524828	Sector: Health care
NSE: N.A.	ISIN Code: INE278D01018

BSE 00:00 | 17 May

125.10

2.20
(1.79%)

OPEN

127.75

HIGH

127.75

LOW

123.15

NSE 05:30 | 01 Jan

BDH Industries Ltd

Add to Watchlist | Add to Portfolio

OPEN	127.75
PREVIOUS CLOSE	122.90
VOLUME	2179
52-Week high	180.00
52-Week low	96.00
P/E	10.02
Mkt Cap.(Rs cr)	72
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

OPEN	127.75
CLOSE	122.90
VOLUME	2179
52-Week high	180.00
52-Week low	96.00
P/E	10.02
Mkt Cap.(Rs cr)	72
Buy Price	0.00
Buy Qty	0.00
Sell Price	0.00
Sell Qty	0.00

BDH Industries Ltd. (BDHINDUSTRIES) - News Sector

Dr Lal Pathlabs Q4 consolidated PAT dips 27% to Rs 62 cr, stock sheds 1%

7.34 pm | 17 May 2022 | Business Standard

Operating revenue rose 12.7% during the quarter to Rs 485.5 cr; Covid-19 and allied segments added roughly 13.6% to Q4 top line
Aurobindo hits 2-year low; dips 11% in a week on USFDA's 6 observations

12.42 pm | 17 May 2022 | Business Standard

Analysts at ICICI Securities expect Aurobindo Pharma's adjusted PAT to de-grow 30.4 per cent year-on-year (YoY) to Rs 557.90 crore in the March 2022 q...
GlaxoSmithKline Pharma reports consolidated net loss of Rs 55 crore

1.05 am | 17 May 2022 | Press Trust of India

Revenue from operations rose to Rs 810 crore for the fourth quarter, compared with Rs 744 crore in the year-ago period, the pharmaceutical major said ...
USFDA rush after 2-year lull: 20-30% new products may be open to inspection

3.01 am | 16 May 2022 | Business Standard

The last two years saw limited physical inspections due to travel restrictions during the pandemic
A first in India: Zydus brings new drug for uncontrolled 'bad' cholesterol

12.04 am | 14 May 2022 | Business Standard

Uncontrolled LDL-c, which poses a major risk of cardiovascular diseases, lacked proper treatment despite patients' lifestyle changes and use of statin...
Cipla looks to invest more in mRNA tech; holds discussions with firms

2.03 am | 12 May 2022 | Business Standard

Speaking to Business Standard, Samina Hamied, executive vice chairperson, Cipla, says one must invest in research and development (R&D) to feed the co...
Cipla will use Covid-19 bulk drugs inventory when demand rises

11.46 pm | 11 May 2022 | Business Standard

The Covid-19 portfolio contributed 5-6 per cent of Cipla's turnover during peak Covid waves, the firm said
Bonus issue fails to lift Ajanta Pharma; stock hits 52-week low on weak Q4

12.27 pm | 11 May 2022 | Business Standard

In Q4FY22, Ajanta's earnings before interest, taxes, depreciation, and amortization declined 20 per cent year-on- year to Rs 207 crore.
Stocks to Watch: SBI, Cipla, Voda Idea, Gujarat Gas, Zensar, MGL, Welspun

8.11 am | 11 May 2022 | Business Standard

Stocks to Watch Today: The primary market too is likely to be abuzz with activity with three IPOs namely - Delhivery, Prudent Corporate Advisory Servi...
Cipla Q4 PAT dips 12% to Rs 362 cr owing to Covid inventory impact

2.26 am | 11 May 2022 | Business Standard

For the full fiscal, Cipla has posted a 4.7% jump in net profit to Rs 2,517 crore, revenue and Ebitda rose 13.6% and 6.4% respectively
Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483

1.22 am | 11 May 2022 | Business Standard

Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days
Rainbow Medicare slumps 17% on debut in worst IPO listing in CY22 so far

11.10 pm | 10 May 2022 | Business Standard

Stock end at Rs 450, Rs 92 below issue price of Rs 542 a share
Rainbow Children's Medicare lists at 7% discount to issue price

10.30 am | 10 May 2022 | Business Standard

The stock listed at Rs 506, a 7% discount when compared with its issue price of Rs 542 per share on the BSE.
75% of Nifty50 stocks trade below 200-DMA; look weak on the charts

11.43 pm | 6 May 2022 | Business Standard

Tech Mahindra and Wipro have tumbled over 30 per cent, while Apollo Hospitals Enterprise and Dr. Reddy's Laboratories have plummeted 22 per cent so fa...
Sanofi India: Strong balance sheet, high cash reserves positives for stock

12.29 am | 6 May 2022 | Business Standard

Products in the price control list and growth of the non-power brand portfolio will be key monitorables
Pfizer sets up drug development centre at Chennai's IIT Research Park

9.34 am | 5 May 2022 | Business Standard

The centre integrates two essential functions under the export-oriented undertaking of Pfizer: Pharmaceutical Sciences (PharmSci) and Global Technolog...
Zomato, L&T Infotech, Solara, TTML plunge over 25% in one month

11.47 am | 4 May 2022 | Business Standard

Shares of Zomato hit a new low of Rs 64.70, down 7 per cent on the BSE in Wednesday's intra-day trade
Alembic Pharma posts Q4 net of Rs 35 cr as India and US businesses grow

7.02 pm | 2 May 2022 | Business Standard

During the quarter, Alembic Pharma's US portfolio strengthened with the acquisition of the balance 40 per cent stake in Aleor Dermaceuticals
Solara Active Pharma slips 15% after Rajender Rao resigns as MD & CEO

11.21 am | 2 May 2022 | Business Standard

Jitesh Devendra, former CEO and Managing Director (MD) of the company will return to Solara as MD, to steer the reset strategy of the Company
Gland Pharma advances 9% on heavy volumes; stock hits 9-week high

12.18 pm | 21 Apr 2022 | Business Standard

At 09:15 AM; around 5.42 million equity shares, representing 3.3 per cent of total equity of Gland Pharma, changed hands on the BSE